The vaccine is also being tested in the UK and the company is expected to announce results from those trials in the first quarter of this year. Novavax isn't the only company with a coronavirus vaccine to experience a major boost in share prices — and big sell-offs from executives. Last year, Moderna's CEO cashed in about $40 million in stock while the company's chief medical offer sold around $60 million. The sell-offs were pre-planned and in line with regulations adopted to avoid insider trading. Read the full Reuters report.